Press coverage about Impax Laboratories (NASDAQ:IPXL) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Impax Laboratories earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.4655786352105 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Impax Laboratories, Inc. (IPXL) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Zacks: Brokerages Anticipate Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $203.66 Million (americanbankingnews.com)
- Comparing Impax Laboratories (IPXL) & Its Peers (americanbankingnews.com)
- Impax to Report Third Quarter 2017 Results … (ih.advfn.com)
- Impax to Report Third Quarter 2017 Results on November 9, 2017 (finance.yahoo.com)
Shares of Impax Laboratories (NASDAQ IPXL) traded up 0.48% during midday trading on Wednesday, hitting $21.10. 170,592 shares of the company were exchanged. The company has a 50-day moving average of $21.00 and a 200 day moving average of $17.01. Impax Laboratories has a one year low of $7.75 and a one year high of $25.70. The company’s market capitalization is $1.57 billion.
Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business had revenue of $202.08 million during the quarter, compared to analysts’ expectations of $195.62 million. During the same quarter in the prior year, the business posted $0.21 earnings per share. Impax Laboratories’s revenue was up 17.1% compared to the same quarter last year. On average, equities research analysts expect that Impax Laboratories will post $0.70 earnings per share for the current fiscal year.
IPXL has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price objective on shares of Impax Laboratories from $20.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, September 11th. Deutsche Bank AG set a $21.00 price objective on shares of Impax Laboratories and gave the stock a “buy” rating in a report on Monday, July 17th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $17.00 price objective on shares of Impax Laboratories in a report on Sunday, September 17th. Zacks Investment Research downgraded shares of Impax Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $16.00 price objective on shares of Impax Laboratories in a report on Friday, June 23rd. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $18.70.
COPYRIGHT VIOLATION WARNING: “Impax Laboratories (IPXL) Given News Impact Rating of 0.17” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/10/11/impax-laboratories-ipxl-given-news-impact-rating-of-0-17.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
What are top analysts saying about Impax Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Impax Laboratories Inc. and related companies.